How can a pharma company survive after its golden goose stops laying?
Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...
3 Fabulous Dividend Stocks to Buy in February
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three ...
3 Dividend Stocks to Double Up on Right Now
AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...
Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...
BioSpace3d
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
Zacks.com on MSN5d
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?
AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...